UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CSPC PHARMACEUTICAL GROUP LIMITED,
CSPC OUYI PHARMACEUTICAL CO., LTD., AND
CONJUPRO BIOTHERAPEUTICS, INC., and APOTEX INC.,
Petitioners,

v.

IPSEN BIOPHARM LTD.,
Patent Owner.

Case No. IPR2025-00505
Patent No. 11,344,552

PETITIONERS' REQUEST FOR ORAL ARGUMENT

Pursuant to the August 14, 2025, Scheduling Order (Paper 14) and 37 C.F.R. § 42.70(a), Petitioners CSPC Pharmaceutical Group Limited, CSPC Ouyi Pharmaceutical Co., Ltd., and Conjurpro Biotherapeutics, Inc. (collectively, "Petitioners"), respectfully request oral argument in the above-referenced proceeding. The oral argument is currently scheduled for May 19, 2026. (Paper 14 at 12.)

Petitioners request an in-person hearing to be held in a Patent Trial and Appeal Board hearing room located at the USPTO's headquarters in Alexandria, Virginia. Petitioners request that each side receive 60 minutes to address any issues raised in the Papers, for a total of a 120-minute hearing. Patent Owner Ipsen Biopharm Ltd. ("Patent Owner") has indicated it agrees to this proposal. Petitioners request the opportunity to reserve a portion of their for rebuttal.

Petitioners request the opportunity to address all issues raised in the Papers, including:

- The Parties' claim constructions;
- The obviousness of claims 1-15 of U.S. Patent No. 11,344,552 in view of the asserted art;
- Patent Owner's failure to present any evidence of secondary considerations that would render any claim non-obvious;

- Any other motions or issues that remain pending at the time of the hearing, including any motions to exclude evidence and responses thereto;
- Any issues raised by Patent Owner in its request for oral argument; and
- And any issues raised by the Board during the oral argument.

Petitioners also request that both (1) a projector with a laptop connector and audio capabilities and (2) an overhead projector ("Elmo") be available for use at oral argument to display possible demonstratives and/or exhibits.

Respectfully submitted,

Dated: April 6, 2026

By: /s/ Lukas D. Toft

Lukas D. Toft (Reg. No. 75,311)
FOX ROTHSCHILD LLP
33 South 6th Street, Suite 3600
Minneapolis, MN 55402
Telephone: (612) 607-7336
Facsimile: (612) 607-7100
ltoft@foxrothschild.com

Joe Chen, Ph.D. (Reg. No. 70,066)
FOX ROTHSCHILD LLP
212 Carnegie Center, Suite 400
Princeton, NJ 08540
Telephone: (609) 844-3024
Facsimile: (609) 896-1469
joechen@foxrothschild.com

Howard S. Suh (*pro hac vice*)
Fox Rothschild LLP
101 Park Avenue, 17th Floor
New York, NY 10178
Telephone: (212) 878-7914
Facsimile: (212) 692-0940
hsuh@foxrothschild.com

Attorneys for Petitioners
CSPC Pharmaceutical Group Limited,
CSPC Ouyi Pharmaceutical Co., Ltd., and
Conjurpro Biotherapeutics, Inc.

CERTIFICATE OF SERVICE

Pursuant to 37 CFR § 42.6(e), the undersigned hereby certifies that on April 6, 2026, the foregoing Petitioners' Request for Oral Argument was served via email, as authorized by the Patent Owner, at the following email addresses:

James M. Glass
jimglass@quinnemanuel.com

Michael Labas
michaellabas@quinnemanuel.com

Angus Chen
anguschen@quinnemanuel.com

Quincy Lu
quincylu@quinnemanuel.com

Catherine Mattes
catherinemattes@quinnemanuel.com

Elizabeth Murphy
elizabethmurphy@quinnemanuel.com

Ross Misskelley
rossmisskelley@quinnemanuel.com

Dated: April 6, 2026

/s/ Luke Toft
Luke Toft (Reg. No. 75, 311)
Counsel for Petitioners